HALO vs. WAT: Halozyme Therapeutics vs. Waters Stock Comparison
How do Halozyme Therapeutics (HALO) and Waters (WAT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Halozyme Therapeutics (HALO) and Waters (WAT) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while WAT is classified in Life Sciences Tools & Services.
| Profile Item | HALO | WAT |
|---|---|---|
| Name | Halozyme Therapeutics Inc. | Waters Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 11.81 billion USD | 44.93 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | March 16, 2004 | November 17, 1995 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | HALO | WAT |
|---|---|---|
| Total Return (1Y) | 50.94% | 27.70% |
| Total Return (3Y, Annualized) | 41.08% | 23.32% |
| Total Return (5Y, Annualized) | 21.68% | 6.27% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | HALO | WAT |
|---|---|---|
| Volatility (1Y, Annualized) | 41.19% | 35.45% |
| Beta (5Y) | 0.96 | 1.13 |
| Max Drawdown (5Y) | -49.06% | -36.47% |
| Avg. Volume (3M) | 2.29M | 816.72K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | HALO | WAT |
|---|---|---|
| Sharpe Ratio (1Y) | 1.13 | 0.66 |
| Sortino Ratio (1Y) | 1.78 | 0.98 |
Profitability
ROE (TTM)
Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than Waters (WAT) at 1.12%, which is closer to a typical peer reading.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
216.38%
- HALO
- 216.38%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.12%
- Max
- 109.18%
- Q3
- 6.23%
- WAT
- 1.12%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Halozyme Therapeutics (HALO) at 26.93% converts revenue to bottom-line profit above its industry’s benchmark range, while Waters (WAT) at 1.76% keeps roughly the typical share for its industry.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.93%
- HALO
- 26.93%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.76%
- Max
- 18.05%
- Q3
- 4.78%
- WAT
- 1.76%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Halozyme Therapeutics (HALO) at 59.84% operates in the top operating margin quartile, ahead of Waters (WAT) at 11.38%, which runs around its industry’s norm.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
59.84%
- Max
- 83.12%
- HALO
- 59.84%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.38%
- Max
- 83.12%
- Q3
- 14.77%
- WAT
- 11.38%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | HALO | WAT |
|---|---|---|
| ROE (TTM) | 216.38% | 1.12% |
| ROA (TTM) | 22.42% | 2.36% |
| Net Margin (TTM) | 26.93% | 1.76% |
| Operating Margin (TTM) | 59.84% | 11.38% |
| Gross Margin (TTM) | 77.74% | 49.83% |
Growth
Revenue Growth
Both Halozyme Therapeutics (HALO) at 37.55% and Waters (WAT) at 6.99% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Halozyme Therapeutics (HALO) at -25.36% and Waters (WAT) at 0.47% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | HALO | WAT |
|---|---|---|
| Revenue Growth (YoY) | 37.55% | 6.99% |
| Revenue Growth (3Y CAGR) | 28.38% | 2.12% |
| EPS Growth (YoY) | -25.36% | 0.47% |
| EPS Growth (3Y CAGR) | 21.14% | -2.84% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Halozyme Therapeutics (HALO) shows current ratio of 3.88 against its industry benchmark, while Waters (WAT) has no reading this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.88
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- HALO
- 3.88
- Q1
- 2.47
- Min
- 0.10
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- WAT
- --
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Waters (WAT) carries debt-to-equity ratio of 0.34 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- HALO
- --
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.34
- Max
- 1.42
- Q3
- 0.65
- WAT
- 0.34
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | HALO | WAT |
|---|---|---|
| Current Ratio (MRQ) | 3.88 | -- |
| Debt / Equity (MRQ) | -- | 0.34 |
| Net Debt / EBITDA | 1.90 | 3.23 |
Dividends
Dividend Yield (TTM)
Neither Halozyme Therapeutics (HALO) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- WAT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Halozyme Therapeutics (HALO) nor Waters (WAT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- HALO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- WAT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | HALO | WAT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while Waters (WAT) at 191.46 sits above its peer range — an unusually expensive price for WAT’s trailing earnings.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.91
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- HALO
- 25.91
- Q1
- 13.30
- Min
- 0.07
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
191.46
- WAT
- 191.46
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Halozyme Therapeutics (HALO) at 6.55 and Waters (WAT) at 8.01 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.55
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- HALO
- 6.55
- Q1
- 3.01
- Min
- 0.01
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.01
- Max
- 58.18
- Q3
- 25.77
- WAT
- 8.01
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Waters (WAT) reports 2.94, ranking against industry peers normally.
HALO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-213.67
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
- HALO
- -213.67
WAT
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- WAT
- 2.94
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | HALO | WAT |
|---|---|---|
| P/E Ratio (TTM) | 25.91 | 191.46 |
| P/S Ratio (TTM) | 6.55 | 8.01 |
| P/B Ratio (MRQ) | -213.67 | 2.94 |
| Free Cash Flow Yield (TTM) | 3.48% | -- |